PUBLIC PERCEPTION OF PHARMACOGENETIC TESTING

Dominik Heuchel¹, Arniko Russ¹, Francesca Wirth², Ulrich Jaehde¹, Lilian M. Azzopardi²





DI-018

¹Klinische Pharmazie, Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany
²Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta dominik.heuchel@web.de

BACKGROUND

By predicting possible ineffectiveness or side-effects, pharmacogenetic testing enables selection of the most suitable drug according to a patient's genetic make-up.¹ There is immense potential in applying pharmacogenetics in clinical practice to implement individualised patient treatment.²

OBJECTIVE

To evaluate the perception of pharmacogenetic testing among the general public in Malta. The focus was on basic attitudes towards pharmacogenetic testing, namely patient knowledge and willingness.

STUDY DESIGN

- A self-administered questionnaire was developed and psychometrically evaluated using a two-round Delphi technique for validation and test-retest method for reliability.
- The developed questionnaire consisted of two sections with a total of 20 questions. Section A dealt with general questions about pharmacogenetic testing and Section B focused on participants' willingness towards pharmacogenetic testing.
- Following ethics approval, 500 participants were recruited by convenience sampling over a 6-week period; 250 participants from public places in eleven different localities and 250 from five community pharmacies in different localities around Malta. Participants in health-oriented occupations were excluded.
- Descriptive statistics were calculated using IBM SPSS version 23.

RESULTS

- Of the 500 participants, 61% were female, mean age was 45 years (range 18-86 years) and 37% were educated to post-secondary level.
- 85% of the participants were not aware of the term 'pharmacogenetic testing'.
- 37% of the participants would be 'very willing' to have a pharmacogenetic test performed to assess the effectiveness of their medications (Figure 1).
- 51% of the participants 'strongly agreed' that a pharmacogenetic test would prevent them from taking an inappropriate drug or dose and 39% would be 'very willing' to have a pharmacogenetic test performed to assess the safety of their medications.
- 70% of the participants identified drugs to treat cancer as the drug class for which they perceived pharmacogenetic testing to be the most important (Figure 2).
- 67% of the participants selected the physician as the professional who should perform the test and 61% selected the hospital as the preferred location to have the test performed.
- 42% of the participants thought the test should be free-of-charge.
- 56% of the participants would expect to have the test result within a few days.
- 40% of the participants 'strongly agreed' that pharmacogenetic testing should be performed routinely.

Figure 1: Participants' willingness towards pharmacogenetic testing as a means of assessing effectiveness of medications (N=500)





Figure 2: Participants' perception of important drug classes for pharmacogenetic testing (N=500)



CONCLUSION

Participants in this study had a positive overall perception of pharmacogenetic testing. The study contributes an understanding of expectations from society regarding pharmacogenetic testing.

References

- 1. Lazaridis KN. Improving therapeutic odyssey: Preemptive pharmacogenomics utility in patient care. Clin Pharmacol Ther. 2017;101(1):39-41.
- 2. American Society of Health-System Pharmacists (ASHP). ASHP statement on the pharmacist's role in clinical pharmacogenomics. *Am J Health-Syst Pharm*. 2015;72(7):579-81.

Acknowledgements

The authors acknowledge the pharmacists and pharmacy staff of the community pharmacies who participated in the study and Professor Liberato Camilleri, Head of the Department of Statistics and Operations Research within the Faculty of Science, University of Malta, for his guidance in the statistical analysis.